Home » Stocks » OTLK

Outlook Therapeutics, Inc. (OTLK)

Stock Price: $2.48 USD -0.04 (-1.59%)
Updated Jun 21, 2021 12:51 PM EDT - Market open
Market Cap 437.49M
Revenue (ttm) 5.85M
Net Income (ttm) -40.50M
Shares Out 150.73M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $2.48
Previous Close $2.52
Change ($) -0.04
Change (%) -1.59%
Day's Open 2.53
Day's Range 2.44 - 2.57
Day's Volume 316,715
52-Week Range 0.58 - 4.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ISELIN, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulatio...

1 week ago - GlobeNewsWire

ISELIN, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulatio...

1 week ago - GlobeNewsWire

ISELIN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation...

3 weeks ago - GlobeNewsWire

ISELIN, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation...

1 month ago - GlobeNewsWire

Live video webcast with Outlook Therapeutics' management team and key opinion leaders on Thursday, May 20th from 11:00 AM – 1:00 PM ET Live video webcast with Outlook Therapeutics' management team and k...

1 month ago - GlobeNewsWire

Penny stocks are ready for a new month; should you watch these 3? The post Hot Penny Stocks to Buy?

Other stocks mentioned: LKCO, SB
1 month ago - PennyStocks

There is something uniquely exciting about being the first company to bring a much-needed product to market. Outlook Therapeutics Inc (NASDAQ:OTLK) is hoping to become the first and only company to comm...

1 month ago - Proactive Investors

MONMOUTH JUNCTION, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formul...

2 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmi...

3 months ago - GlobeNewsWire

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines ...

Other stocks mentioned: BHC, DMAC, IBIO, ONCY
4 months ago - Benzinga

MONMOUTH JUNCTION, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

4 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

4 months ago - GlobeNewsWire

Topline results from open-label safety study (NORSE THREE) on target for Q2 2021 Topline results from open-label safety study (NORSE THREE) on target for Q2 2021

4 months ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

Other stocks mentioned: HOG, TXN, ADS, BDGE, BRO, EVLO, MSM ...
4 months ago - Benzinga

Overallotment option on recent public offering partially exercised by underwriter

4 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the firs...

4 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the firs...

4 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the firs...

4 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

5 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

5 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

6 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

7 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

7 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

7 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

7 months ago - GlobeNewsWire

Live moderated video webcast discussion among members of management and Key Opinion Leader Firas M. Rahhal, MD on Thursday, October 29th at 10:00 AM ET Live moderated video webcast discussion among memb...

7 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

8 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...

8 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic form...

8 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthal...

9 months ago - GlobeNewsWire

The share price of Outlook Therapeutics fell sharply due to the anticipated differentiation between LYTENAVA and LUCENTIS.

9 months ago - Seeking Alpha

MONMOUTH JUNCTION, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalm...

9 months ago - GlobeNewsWire

Oncobiologics, Inc. (OTLK) delivered earnings and revenue surprises of -83.33% and -100.00%, respectively, for the quarter ended June 2020.

10 months ago - Zacks Investment Research

MONMOUTH JUNCTION, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalm...

10 months ago - GlobeNewsWire

Oncobiologics, Inc. (OTLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

10 months ago - Zacks Investment Research

MONMOUTH JUNCTION, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophtha...

11 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., July 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophtha...

11 months ago - GlobeNewsWire

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

MONMOUTH JUNCTION, N.J., June 25, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA...

11 months ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., June 17, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-a...

1 year ago - GlobeNewsWire

Live moderated video webcast discussion with President, CEO and CFO Lawrence Kenyon, on Wednesday, June 17th at 2:00 PM ET, immediately followed by an interactive Q&A session Live moderated video webcas...

1 year ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-a...

1 year ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-ap...

1 year ago - GlobeNewsWire

MONMOUTH JUNCTION, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-ap...

1 year ago - GlobeNewsWire

CRANBURY, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved...

1 year ago - GlobeNewsWire

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

CRANBURY, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approve...

1 year ago - GlobeNewsWire

CRANBURY, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approve...

1 year ago - GlobeNewsWire

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved o...

1 year ago - GlobeNewsWire

CRANBURY, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”),  a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ...

1 year ago - GlobeNewsWire

About OTLK

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLex... [Read more...]

Industry
Biotechnology
IPO Date
May 13, 2016
CEO
Lawrence Kenyon
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
OTLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is 5.33, which is an increase of 114.92% from the latest price.

Price Target
$5.33
(114.92% upside)
Analyst Consensus: Strong Buy